Advance Stroke and CNS Drug Development with Human-Relevant BBB Organoids
Blood–Brain Barrier (BBB) organoids are advanced three-dimensional (3D) in vitro models designed to recapitulate the structural and functional complexity of the human blood–brain barrier. These organoids are typically composed of brain microvascular endothelial cells, pericytes, astrocytes, and supporting extracellular matrix components, forming a multicellular architecture that closely mimics the in vivo BBB.
Ace Therapeutics' BBB Organoids provide a powerful in vitro platform for investigating BBB biology and evaluating novel stroke therapies in a controlled and human-relevant environment.
Download this poster to learn about:
Access the poster today and explore how BBB organoids can help accelerate your stroke and CNS drug development programs.
A systematic introduction to Ace Therapeutics' preclinical stroke research capabilities and cutting-edge technology platforms.
Our models combine primary endothelial and glial co-culture systems to simulate the structural and functional integrity of the BBB under both normal and ischemic conditions.
Our customized in vitro models of stroke and advanced cell-based assay platform accelerate the discovery of novel stroke therapies.
The OGD model is achieved by replacing the oxygen- and glucose-rich medium with an oxygen- and glucose-deprived medium equilibrated with nitrogen.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.